Cases & Deals

BioMarin expands global patent portfolio related to KUVAN

Clients BioMarin Pharmaceutical, Inc.

Jones Day advised BioMarin Pharmaceutical, Inc. in the expansion of a global patent portfolio relating to KUVAN (sapropterin dihydrochloride), which is indicated for the treatment of hyperphenylalaninemia due to tetrahydrobiopterin-responsive phenylketonuria (PKU).

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.